Clinical trials: Influenza in Humans
Influenza, Influenza Immunisation
Age and Response to Flu Vaccines
The study will be designed as a prospective surveillance of the immune response to seasonal influenza vaccination in 240 healthy children and adults ages 9 and over.
- Trial name
- NCT03328325
- Testing
- Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Infection
Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults
The purpose of this study is to evaluate the safety and immunogenicity of a single subcutaneous injection of TAK-850 as compared to intramuscular injection of TAK-850 in healthy Japanese adults
- Trial name
- NCT02313155
- Testing
- Subcutaneous injection of TAK-850, Intramuscular injection of TAK-850
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza
Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains
The study is to assess whether the virosomal influenza vaccine for season 2012/2013 fulfills the EMA requirements for re-registration of influenza vaccines.
- Trial name
- NCT01631071
- Testing
- Virosomal influenza vaccine
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults
The aim of the study is to evaluate the safety and immunogenicity of the 2015-2016 formulations of Fluzone Quadrivalent and Fluzone Intradermal Quadrivalent vaccines in adults 18 to < 65 years of age, and of the 2015-2016…
- Trial name
- NCT02563093
- Testing
- Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
- Where
- 4 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pandemic Influenza
A/H5N1/LT Dose Ranging Study
This is a Phase 2, randomized, blinded, clinical trial. Up to 500 eligible subjects will be enrolled and randomized in a 1:2:2:1:2:2 ratio into one of six groups, and vaccinated in this study.
- Trial name
- NCT00908687
- Testing
- A/H5N1, LT Adjuvant Patch
- Where
- 6 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Influenza
Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A
In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the…
- Trial name
- NCT00540592
- Testing
- GlaxoSmithKline Biologicals' influenza vaccine GSK576389A, Fluarix
- Where
- 30 sites in Germany, Netherlands and 2 more
- Volunteers
- 2,007 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza A Subtype H5N1 Infection
Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1
This is a first-in-human study of safety and immunogenicity of an A/H5N1 inactivated whole cell vaccine when given in two injections in two doses (low and high) compared to a placebo in 76 healthy adult subjects in Vietnam.
- Trial name
- NCT02171819
- Testing
- IVACFLU-A/H5N1, 7.5 mcg, IVACFLU-A/H5N1, 15 mcg
- Where
- Vietnam
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Human Influenza
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of cell-derived, trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years and the antibody response to each…
- Trial name
- NCT01880697
- Testing
- TIVc
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The purpose of the study is to evaluate the safety and immunogenicity of GSK Biologicals' influenza vaccine GSK2340272A.
- Trial name
- NCT00951041
- Testing
- GSK investigational vaccine GSK2340272A, GSK investigational vaccine GSK2340269A
- Where
- 3 sites in Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Virus Diseases
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to areas of inflammation.
- Trial name
- NCT02927431
- Testing
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Oseltamivir 75 mg
- Where
- 8 sites in United States, Romania and 2 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Influenza
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
- Trial name
- NCT00867139
- Testing
- TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Fred Hutchinson Cancer Center
Influenza Disease
Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age
This Study Aims to Evaluate the Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent…
- Trial name
- NCT01346592
- Testing
- Trivalent split influenza vaccine (TIV), MF59-adjuvanted trivalent influenza vaccine (aTIV), Licensed comparator trivalent split influenza vaccine (comparator TIV)
- Where
- 34 sites in Argentina, Australia and 3 more
- Volunteers
- 6,104 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Seasonal Influenza
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase…
- Trial name
- NCT06602024
- Testing
- mRNA-1010, Fluarix®, Influsplit® Tetra
- Where
- 301 sites in United States, Belgium and 9 more
- Volunteers
- 40,805 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Influenza Vaccines
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2584786A in healthy children 6 to 35 months of age.
- Trial name
- NCT01195779
- Testing
- GSK Bio's influenza vaccine GSK2584786A, different formulations, GSK Bio's influenza vaccine GSK2321138A, Fluarix™
- Where
- Spain
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England
This pilot study, to be conducted in the 2017/2018 influenza season, is a safety surveillance study using passive surveillance enhanced with a reporting card system to report adverse events of interest (AEIs) after Flu…
- Trial name
- NCT03278067
- Testing
- Enhanced vaccine safety surveillance
- Where
- United Kingdom
- Volunteers
- 23,939 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Mechanisms of Severe Acute Influenza Consortium (MOSAIC)
The ultimate goal of this collaborative, intensive study is to discover new and effective treatments and to develop better vaccines that can be used in future outbreaks of Influenza A.
- Trial name
- MOSAIC (NCT00965354)
- Where
- 8 sites in United Kingdom
- Volunteers
- 131 people
- Sponsor
- Imperial College London
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus…
- Trial name
- CAPSTONE 1 (NCT02954354)
- Testing
- Baloxavir Marboxil, Oseltamivir
- Volunteers
- 1,436 people
- Sponsor
- Shionogi
Influenza, Human, Immune Response
Immunologic Response to FluMist vs. Flucelvax
The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-21 years of age.
- Trial name
- NCT03982069
- Testing
- FluMist live attenuated influenza vaccine, Flucelvax inactivated influenza vaccine
- Where
- 2 sites in United States
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Richard Zimmerman MD
Influenza
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years
The aim of the trial is to evaluate immunogenicity and safety of the quadrivalent influenza vaccine (QIV) and the trivalent influenza vaccine (TIV) (split-virion inactivated) Northern Hemisphere (NH) 2015 2016 seasonal…
- Trial name
- NCT02550197
- Testing
- Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016, Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
- Where
- 5 sites in South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company